TJ011133 + pembrolizumab

**TJ011133 + pembrolizumab** is an investigational combination therapy being evaluated for the treatment of relapsed or refractory advanced solid tumors and lymphoma. TJ011133 is a monoclonal antibody that targets CD47, a protein that enables tumor cells to evade immune detection; by binding to CD47, TJ011133 enhances the immune-mediated destruction of tumor cells. Pembrolizumab (Keytruda) is an FDA-approved anti-PD-1 monoclonal antibody that inhibits the programmed cell death-1 (PD-1) pathway, thereby activating T cells against cancer. The combination aims to promote both innate and adaptive immune responses against tumors. This therapy is currently under investigation in a Phase 1 clinical trial for safety, tolerability, and preliminary efficacy in specific patient populations[1][2][3][6].

Brand names

Keytruda

Other names

TJ011133 plus pembrolizumabTJ-011133 plus pembrolizumabTJ 011133 plus pembrolizumabTJ011133 and pembrolizumabTJ-011133 and pembrolizumabTJ 011133 and pembrolizumabTJ011133 combination with pembrolizumabTJ-011133 combination with pembrolizumabTJ 011133 combination with pembrolizumabTJ011133 + Keytruda